Fox Chase patients may be eligible to receive third COVID-19 vaccine dose – Read More

MENU

Alexander Kutikov, MD, FACS

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

Secondary Location

Fox Chase Cancer Center Huntingdon Pike
8 Huntingdon Pike
Rockledge, PA 19046

About

Chief, Division of Urology and Urologic Oncology

Professor, Department of Surgical Oncology

Roberta R. Scheller Chair in Urologic Oncology

American Urological Association's Urology Care Foundation, Prostate Health Committee Panel Member

Treatment Focus

Minimally Invasive Surgery, Robotic Surgery, Laparoscopic Surgery, Traditional Open Surgery
Prostate Cancer: robotic and open radical nerve-sparing prostatectomy
Bladder Cancer: urinary diversion, orthotopic neobladder reconstruction
Kidney Cancer: kidney-sparing approaches, robotic, laparoscopic, open kidney surgery.
Adrenal masses: minimally-invasive adrenal surgery and extensive expertise in treatment of adrenal incidentalomas.

Research Program

Key Awards

Language(s) Other than English

Russian

Treatment Philosophy

I am a surgical specialist who treats tumors of the adrenal, kidney, prostate, bladder, testis, and other genitourinary organs. Working closely with other members of the Fox Chase multidisciplinary team, I make certain that my patients are aware of all the choices that today's cutting edge oncological care has to offer, regardless of whether these treatments take place inside or outside the operating room.

When surgery is necessary, I strive to offer the best operation that fits an individual's particular condition and circumstance. Indeed, my unique fellowship training in both traditional open surgery and minimally-invasive approaches such as laparoscopy and robotics, allows me to offer a wide range of options that optimize oncological outcomes and minimize recovery time. For example, I am skilled at both open and robot-assisted nerve-sparing prostatectomy and open, laparoscopic, and robotic kidney surgery. Particularly, I have advanced expertise in kidney preservation. For patients with bladder cancer, I am able to offer both bladder-sparing approaches and the latest techniques in continent urinary reconstruction. Furthermore, I have a particular interest and expertise in treatment of various tumors and conditions that stem from the adrenal gland.

As a clinician at an academic institution such as Fox Chase, I actively participate in medical research. In particular, my academic interests focus on kidney, prostate, bladder, and adrenal disease. Being an active contributor to the medical literature, I hope to offer my patients the most up-to-date information on medical progress and, if necessary, help them enroll into appropriate clinical trials — many of which are only available through Fox Chase.

Modern oncology offers patients tremendous hope; however, today's treatment options can be overwhelming, especially to those who are trying to cope with the shock of a recent cancer diagnosis. I greatly appreciate the toll that such a diagnosis can take not only on the patient, but also on his or her family. I hope to bring to every one of my patients a sense of understanding and compassion that can help us effectively work together to achieve the best outcome that modern medicine has to offer.

 
Education and Training

Educational Background

  • Fellow, Society of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
  • Chief Resident, Urology, University of Pennsylvania, Philadelphia, PA, 2007-2008
  • Resident, Urology, University of Pennsylvania, Philadelphia, PA, 2004-2007
  • MD, Harvard Medical School, Harvard-MIT Health Sciences and Technology Program, Boston, MA, 2003

Certifications

  • American Board of Urology, Board Certified

Memberships

  • Society of Urologic Oncology
  • American Urological Association
  • American College of Surgeons
  • Philadelphia Urological Society

Honors & Awards

  • Young Urologist of the Year, Mid-Atlantic Section, American Urological Association, 2021
  • Philadelphia Magazine Top Doctors, 2017-21
  • Best Doctors in America® , 2019-2020, Urology
  • Everyday Hero Award, Pennsylvania Medical Society (PAMED), 2018
  • America's Top Doctors®2016-17
  • BJU International Journal Best Mobile App Award for drawMD Urology iPad Application, American Urological Association Meeting, San Diego, CA, 2013
  • Mid-Atlantic AUA Young Investigator Representative to the AUA’s Research Forum, American Urological Association Meeting, Washington, DC, 2011
  • CaPSURE Scholar, CaPSURE Scholars Program in Prostate Cancer Outcomes Research, 2009-10
  • American College of Surgeons Excellence in Research Award 96th Annual Clinical Congress, Surgical Forum, 2010
Patient Stories

Donna McAllister

Bladder Cancer

Donna McAllister

Bladder Cancer

I was treated with compassion, given hope, and kept informed of every facet of my treatment.

Edward Enoch

Prostate Cancer

Edward Enoch

Prostate Cancer

My name is Edward Enoch, and I am from Lansdale, Pennsylvania. I was sixty years old and two years retired when my life took a startling turn.

Like millions of other retirees, my wife Janice and I were updating our health insurance. We met with an agent who asked that I schedule a routine checkup. I thought nothing of it at the time—after all, I had no complaints about my health. However, once I received the results of my blood test, the confidence I had regarding my health started to waver.

Charles "Cha" Goods

Prostate Cancer

Charles "Cha" Goods

Prostate Cancer

I’ve been a tennis coach for nearly 17 years, the last dozen at Legacy Youth Tennis and Education in Philadelphia. I run group clinics and offer private lessons. I specialize in movement and footwork training, as well as video-based training. My students range from kids as young as five to professional tennis players. I’m an active coach. When I teach my students how to do something, I want to show them I can do it. They’re amazed at how good I am!

Annie Dunn

Kidney Cancer

Annie Dunn

Kidney Cancer

I have always enjoyed being social and keeping busy with a handful of hobbies. At 68, I spent most of my time cycling with my husband Tom, going on walks, reading whatever I could find, and socializing with friends. Up until recently, those things had always been a regular part of my life. However, after being diagnosed with kidney cancer amid the COVID-19 pandemic, those activities had to take a back seat.

Thomas Nixon

Kidney Cancer

Thomas Nixon

Kidney Cancer

I never expected what I heard, that my cancer was aggressive. I went back to my primary care doctor and asked if I should get a second opinion. He told me I should, so I was referred to Dr. Alexander Kutikov, a surgical oncologist at Fox Chase Cancer Center. This was all during the time that COVID-19 was beginning to ramp up in the United States. I was concerned that my surgery would be rescheduled or even canceled.

Pages

Research Profile

Research Program

Research Interests

Dr. Kutikov has authored over 140 peer-reviewed publications.  His current research interests include understanding carcinogenesis of genitourinary cancers, risk-stratification of surgical outcomes, and quantification of competing risks.  He serves on editorial boards of academic journals, including being the Associate Editor of Digital Media for European Urology, the field of Urology's leading academic publication.

Dr. Kutikov also has significant interests in harnessing web and mobile technology to improve patient engagement and quality of care.  He is a co-founder of several ventures that strive to improve physician education and patient care.  

Lab Overview

In collaboration with Vladimir Kolenko, MD, PhD, and Robert Uzzo, MD, our research efforts span the basic and the clinical sciences. Our work focuses on understanding the process of renal and prostatic carcinogenesis and assessing novel therapeutic regimens for the treatment of urological cancers.

As part of our work, we explore the role of zinc in development and progression of prostate malignancy.  Zinc concentrations diminish early in the course of prostate carcinogenesis—prior to histopathological changes—and continue to decline during progression toward castration-resistant growth. The objective of research in our laboratory is to test and advance an emerging paradigm that intracellular zinc deficiency augments malignant potential of prostate cancer cells and, therefore, promotes prostate tumorigenesis. We are also investigating the role of zinc chelators as potential therapeutic agents for the treatment of castration-resistant prostate cancer. Work performed by Dr. Kolenko indicates that treatment of prostate cancer cells with the zinc chelating agent TPEN induces selective down-regulation of X-linked inhibitor of apoptosis protein (XIAP) and sensitizes cancer cells to cytotoxic agents. Importantly, the observed effect is not limited to prostate cancer, as TPEN reduces expression of XIAP in malignant cell lines of various origins, e.g. colon, ovarian, leukemia, breast and cervical.

The second major theme of our research is to determine the mechanism of tyrosine kinase inhibitor (TKIs)-resistance in genitourinary tumors. Our studies reveal that TKI-resistance coincides with the loss of phosphatase and tensin homolog (PTEN) protein expression in prostate and renal malignant cells. On the contrary, expression of PTEN sensitizes prostate and renal tumors to multi-targeted tyrosine kinase inhibitor sunitinib both in vitro and in vivo. In addition, our studies indicate that an increase in expression of IL-6 and IL-8 correlates with sunitinib and pazopanib resistance in prostate and renal tumor cells. Use of a reliable biomarker for TKI response, harbors promise both in the clinical and research settings.

In the clinical arena, we focus our efforts on addressing quantification of competing risks of death for patients with urologic malignancies, investigating the biology and natural history of small renal masses, improving reporting and risk-stratification of surgical outcomes for patients with kidney cancer, and addressing clinical approaches to patients with adrenal cancers and incidental adrenal masses.

Publications

Selected Publications

A. G. McIntosh, D. C. Parker, B. L. Egleston, R. G. Uzzo, H. Haseebuddin, S. S. Joshi, R. Viterbo, R. E. Greenberg, D. Y. T. Chen, M. C. Smaldone, and Kutikov, “Prediction of Significant Estimated Glomerular Filtration Rate Decline Following Renal Unit Removal to Aid in the Clinical Choice between Radical and Partial Nephrectomy in Patients with Renal Mass and Normal Renal Function,” BJU Int, May 2019. PubMed

H. Borgmann, M. Cooperberg, D. Murphy, S. Loeb, J. N’Dow, M. J. Ribal, H. Woo, M. Rouprêt, A. Winterbottom, C. Wijburg, M. Wirth, J. Catto, and A. Kutikov, “Online Professionalism—2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media,” European Urology, pp. 1–7, Aug. 2018. PubMed

M. C. Smaldone, B. Egleston, J. M. Hollingsworth, B. K. Hollenbeck, D. C. Miller, T. M. Morgan, S. P. Kim, A. Malhotra, E. Handorf, Y.-N. Wong, R. G. Uzzo, and A. Kutikov, “Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data,” Med Care, vol. 55, no. 4, pp. 398–404, Apr. 2017. PubMed

N. Waingankar, K. Mallin, M. Smaldone, B. L. Egleston, A. Higgins, D. P. Winchester, R. G. Uzzo, and A. Kutikov, “Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy,” BJU Int, vol. 120, no. 2, pp. 239–245, Aug. 2017. PubMed

B. T. Ristau, D. Y. T. Chen, J. Ellis, A. Malhotra, L. DeMora, R. B. Parsons, B. Milestone, M. Brody, R. Viterbo, R. Greenberg, M. Smaldone, R. Uzzo, J. Anaokar, and A. Kutikov, “Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy,” The Journal of Urology, Oct. 2017. PubMed

S. P. Kim, S. C. Campbell, I. Gill, B. R. Lane, H. Van Poppel, M. C. Smaldone, A. Volpe, and A. Kutikov, “Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses,” European Urology, vol. 72, no. 1, pp. 64–75, Jul. 2017. PubMed

A. Kutikov, H. H. Woo, and J. W. Catto, “Urology Tag Ontology Project: Standardizing Social Media Communication Descriptors,” European Urology, vol. 69, no. 2, pp. 183–185, Feb. 2016. PubMed

A. Kutikov, M. C. Smaldone, R. G. Uzzo, M. Haifler, G. Bratslavsky, and B. C. Leibovich, “Renal Mass Biopsy: Always, Sometimes, or Never?,” European Urology, vol. 70, no. 3, pp. 403–406, Sep. 2016. PubMed

E. R. Plimack, R. L. Dunbrack, T. A. Brennan, M. D. Andrake, Y. Zhou, I. G. Serebriiskii, M. Slifker, K. Alpaugh, E. Dulaimi, N. Palma, J. Hoffman-Censits, M. Bilusic, Y.-N. Wong, A. Kutikov, R. Viterbo, R. E. Greenberg, D. Y. T. Chen, C. D. Lallas, E. J. Trabulsi, R. Yelensky, D. J. McConkey, V. A. Miller, E. A. Golemis, and E. A. Ross, “Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer,” European Urology, vol. 68, no. 6, pp. 959–967, Dec. 2015. PubMed

S. Ginzburg, R. Uzzo, J. Walton, C. Miller, D. Kurz, T. Li, E. Handorf, R. Gor, A. Corcoran, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, M. C. Smaldone, and A. Kutikov, “Residual Parenchymal Volume, Not Warm Ischemia Time, Predicts Ultimate Renal Functional Outcomes in Patients Undergoing Partial Nephrectomy.,” Urology, vol. 86, no. 2, pp. 300–306, Aug. 2015.   PubMed

B. Shuch, A. Amin, A. J. Armstrong, J. N. Eble, V. Ficarra, A. Lopez-Beltran, G. Martignoni, B. I. Rini, and A. Kutikov, “Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity,” European Urology, vol. 67, no. 1, pp. 85–97, Jan. 2015. PubMed

E. R. Plimack, J. H. Hoffman-Censits, R. Viterbo, E. J. Trabulsi, E. A. Ross, R. E. Greenberg, D. Y. T. Chen, C. D. Lallas, Y.-N. Wong, J. Lin, A. Kutikov, E. Dotan, T. A. Brennan, N. Palma, E. Dulaimi, R. Mehrazin, S. A. Boorjian, W. K. Kelly, R. G. Uzzo, and G. R. Hudes, “Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity,” J. Clin. Oncol., vol. 32, no. 18, pp. 1895–1901, Jun. 2014. PubMed

A. Minervini, M. Carini, R. G. Uzzo, R. Campi, M. C. Smaldone, and A. Kutikov, “Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surface-Intermediate-Base Margin Score.,” European Urology, Jun. 2014.    PubMed

A. Kutikov, P. Makhov, K. Golovine, D. J. Canter, M. Sirohi, R. Street, J. Simhan, R. G. Uzzo, and V. M. Kolenko, “Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer,” Urology, vol. 78, no. 4, pp. 968.e7–11, Oct. 2011. PubMed

A. Kutikov, M. C. Smaldone, B. L. Egleston, B. J. Manley, D. J. Canter, J. Simhan, S. A. Boorjian, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, and R. G. Uzzo, “Anatomic Features of Enhancing Renal Masses Predict Malignant and High-Grade Pathology: A Preoperative Nomogram Using the RENAL Nephrometry Score,” European Urology, vol. 60, no. 2, pp. 241–248, Aug. 2011.   PubMed

A. Kutikov, B. L. Egleston, Y.-N. Wong, and R. G. Uzzo, “Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram,” J. Clin. Oncol., vol. 28, no. 2, pp. 311–317, Jan. 2010. PubMed

A. Kutikov and R. G. Uzzo, “The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth,” The Journal of Urology, vol. 182, no. 3, pp. 844–853, Sep. 2009. PubMed

Additional Publications

Full List of Publications

Ratings

410 PATIENT SATISFACTION REVIEWS

Our Patient Satisfaction Rating is an average of all responses to care provider related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more.

OVERALL RATING

4.9 / 5.0

RATINGS BREAKDOWN

  • 4.9
  • 4.9
  • 4.9
  • 4.9
  • 4.8

107 PATIENT COMMENTS

  • 5.0
    June 17, 2021
    Dr. Kutikov came with good credentials.
  • 4.0
    May 29, 2021
    I was very satisfied with my experience.
  • 5.0
    May 20, 2021
    Very impressed with the followup and scheduling process.
  • No Star Ratings Available May 18, 2021
    very satisfied with Dr. Kutikov
  • No Star Ratings Available May 17, 2021
    Dr Kutikov is wonderful!
  • No Star Ratings Available May 17, 2021
    excellent provider, good listener clear and direct
  • No Star Ratings Available May 11, 2021
    I feel comfortable discussing my health concerns with Dr. Kutikov , physician assistant, [...].
  • 5.0
    May 10, 2021
    Overall excellent care
  • No Star Ratings Available May 03, 2021
    Dr Kutikov was excellent in every way.
  • 5.0
    May 02, 2021
    In late [...] Doctor Kutikov successfully performed major surgery on me to remove part of my ureter. He provided excellent care to me during surgery, while in the hospital recovering and during follow up care. My wife and I are very happy that he took me on as a patient. I am grateful for his and his team's services.
  • 5.0
    April 28, 2021
    This was an outstanding experience starting with the receptionist, the P.A., Dr. Kutikov, his nurse, [...] nurse, [...] and the staff at the CT Imaging department. I received caring and concerned treatment from each and every one of them. Additionally, Dr. Kutikov's receptionist made at least three calls over to the hospital to get me in for a CT Scan that day that had not been scheduled in advance. I could not have been happier with the people from Fox Chase who dealt with me that day.
  • No Star Ratings Available April 28, 2021
    Dr. Kutikov helped us make the right decision for our case. he is never in a hurry during our appt. Very personable (great bed side manner)
  • 5.0
    April 26, 2021
    the doctor and team were exceptionally courteous before and throughout the face to face visit. Dr. kutokof is very reassuring and set my mind at ease.
  • 5.0
    April 21, 2021
    I feel very confident coming to Fox Chase for treatment. Dr. Kutikov and the staff are wonderful.
  • 5.0
    April 15, 2021
    Dr. Kutikov and his team are the best ever!!
  • No Star Ratings Available April 14, 2021
    I recommended a friend to Dr. Kutikov and he will be moving forward with care and a possible prostatectomy
  • No Star Ratings Available April 09, 2021
    Great experience!
  • 4.2
    April 09, 2021
    Keep the professional attitude your people are showing to the patient .
  • No Star Ratings Available April 03, 2021
    vary knowledgeable.
  • No Star Ratings Available April 02, 2021
    A-plus!!
LOAD MORE

Connect with Fox Chase